This is the authors' abstract. We don't add key points for this paper.
Real-life and longer-term safety studies are often in progress when direct-to-consumer advertising for a new drug begins. The authority to ban direct-to-consumer advertising is included in two drug-safety bills that have been wending their way through the legislative process. Dr. Miriam Shuchman reports.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Miriam Shuchman (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: